Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.49 Billion DKK | 39047.28% |
| 2022 | -3.84 Million DKK | 98.54% |
| 2021 | -263.31 Million DKK | -158.56% |
| 2020 | 449.62 Million DKK | 242.09% |
| 2019 | -316.43 Million DKK | 0.96% |
| 2018 | -319.5 Million DKK | -203.89% |
| 2017 | 307.55 Million DKK | 356.71% |
| 2016 | 67.34 Million DKK | -19.36% |
| 2015 | 83.5 Million DKK | 303.13% |
| 2014 | 20.71 Million DKK | 16.11% |
| 2013 | 17.84 Million DKK | 161.36% |
| 2012 | -29.07 Million DKK | 89.85% |
| 2011 | -286.61 Million DKK | 39.0% |
| 2010 | -469.89 Million DKK | -49.97% |
| 2009 | -313.32 Million DKK | -40.26% |
| 2008 | -223.38 Million DKK | -361.93% |
| 2007 | -48.36 Million DKK | 76.12% |
| 2006 | -202.52 Million DKK | -102.33% |
| 2005 | -100.09 Million DKK | -21.59% |
| 2004 | -82.32 Million DKK | -138.46% |
| 2003 | 214.03 Million DKK | 903.15% |
| 2002 | -26.65 Million DKK | 71.49% |
| 2001 | -93.48 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 265.89 Million DKK | 306.29% |
| 2024 Q1 | -128.89 Million DKK | -114.09% |
| 2023 Q2 | 560.2 Million DKK | 49.41% |
| 2023 FY | 1.49 Billion DKK | 39047.28% |
| 2023 Q3 | -331.09 Million DKK | -159.1% |
| 2023 Q4 | 914.83 Million DKK | 376.31% |
| 2023 Q1 | 374.93 Million DKK | 52.06% |
| 2022 FY | -3.84 Million DKK | 98.54% |
| 2022 Q3 | 129.24 Million DKK | 178.52% |
| 2022 Q1 | -173.09 Million DKK | -234.47% |
| 2022 Q2 | -164.59 Million DKK | 4.91% |
| 2022 Q4 | 246.56 Million DKK | 90.77% |
| 2021 FY | -263.31 Million DKK | -158.56% |
| 2021 Q1 | -81.08 Million DKK | 74.92% |
| 2021 Q2 | -94.92 Million DKK | -17.08% |
| 2021 Q3 | -35.55 Million DKK | 62.54% |
| 2021 Q4 | -51.75 Million DKK | -45.55% |
| 2020 Q2 | 135.93 Million DKK | -75.93% |
| 2020 Q3 | 62.56 Million DKK | -53.97% |
| 2020 Q4 | -323.24 Million DKK | -616.63% |
| 2020 FY | 449.62 Million DKK | 242.09% |
| 2020 Q1 | 564.74 Million DKK | 1631.17% |
| 2019 Q1 | -97.65 Million DKK | -12.68% |
| 2019 Q2 | -94.17 Million DKK | 3.56% |
| 2019 Q3 | -87.71 Million DKK | 6.86% |
| 2019 FY | -316.43 Million DKK | 0.96% |
| 2019 Q4 | -36.88 Million DKK | 57.95% |
| 2018 Q2 | -103.1 Million DKK | 39.55% |
| 2018 FY | -319.5 Million DKK | -203.89% |
| 2018 Q1 | -170.57 Million DKK | 5.73% |
| 2018 Q4 | -86.66 Million DKK | -312.2% |
| 2018 Q3 | 40.84 Million DKK | 139.61% |
| 2017 FY | 307.55 Million DKK | 356.71% |
| 2017 Q3 | 441.55 Million DKK | 635.66% |
| 2017 Q2 | 60.02 Million DKK | 559.23% |
| 2017 Q1 | -13.07 Million DKK | -108.7% |
| 2017 Q4 | -180.95 Million DKK | -140.98% |
| 2016 Q4 | 150.14 Million DKK | 18.25% |
| 2016 Q2 | -38.55 Million DKK | 77.48% |
| 2016 Q1 | -171.22 Million DKK | -1116.63% |
| 2016 FY | 67.34 Million DKK | -19.36% |
| 2016 Q3 | 126.97 Million DKK | 429.32% |
| 2015 FY | 83.5 Million DKK | 303.13% |
| 2015 Q4 | 16.84 Million DKK | 121.41% |
| 2015 Q3 | -78.68 Million DKK | -162.95% |
| 2015 Q2 | 125 Million DKK | 97.16% |
| 2015 Q1 | 63.4 Million DKK | -58.27% |
| 2014 Q2 | -66.8 Million DKK | -1409.8% |
| 2014 Q4 | 151.93 Million DKK | 875.18% |
| 2014 Q3 | -19.6 Million DKK | 70.66% |
| 2014 FY | 20.71 Million DKK | 16.11% |
| 2014 Q1 | 5.1 Million DKK | -71.02% |
| 2013 Q3 | 32.4 Million DKK | 224.0% |
| 2013 Q4 | 17.59 Million DKK | -45.69% |
| 2013 FY | 17.84 Million DKK | 161.36% |
| 2013 Q1 | -39.2 Million DKK | 44.29% |
| 2013 Q2 | 10 Million DKK | 125.51% |
| 2012 FY | -29.07 Million DKK | 89.85% |
| 2012 Q4 | -70.36 Million DKK | -295.46% |
| 2012 Q3 | 36 Million DKK | 89.47% |
| 2012 Q2 | 19 Million DKK | 166.2% |
| 2012 Q1 | -28.7 Million DKK | -172.51% |
| 2011 Q4 | 39.58 Million DKK | 191.84% |
| 2011 FY | -286.61 Million DKK | 39.0% |
| 2011 Q1 | -118.6 Million DKK | -4.31% |
| 2011 Q2 | -134.7 Million DKK | -13.58% |
| 2011 Q3 | -43.1 Million DKK | 68.0% |
| 2010 Q2 | -44.6 Million DKK | 58.86% |
| 2010 Q1 | -108.4 Million DKK | -57.73% |
| 2010 Q4 | -113.69 Million DKK | 38.81% |
| 2010 FY | -469.89 Million DKK | -49.97% |
| 2010 Q3 | -185.8 Million DKK | -316.59% |
| 2009 Q2 | -96 Million DKK | -30.43% |
| 2009 Q1 | -73.6 Million DKK | 0.0% |
| 2009 FY | -313.32 Million DKK | -40.26% |
| 2009 Q4 | -68.72 Million DKK | -1.96% |
| 2009 Q3 | -67.4 Million DKK | 29.79% |
| 2008 FY | -223.38 Million DKK | -361.93% |
| 2007 FY | -48.36 Million DKK | 76.12% |
| 2006 FY | -202.52 Million DKK | -102.33% |
| 2005 FY | -100.09 Million DKK | -21.59% |
| 2004 FY | -82.32 Million DKK | -138.46% |
| 2003 FY | 214.03 Million DKK | 903.15% |
| 2002 FY | -26.65 Million DKK | 71.49% |
| 2001 FY | -93.48 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ALK-Abelló A/S | 666 Million DKK | -124.853% |
| Genmab A/S | 5.32 Billion DKK | 71.856% |
| Gubra A/S | -49.41 Million DKK | 3130.38% |
| Novo Nordisk A/S | 102.57 Billion DKK | 98.54% |
| Orphazyme A/S | -27.04 Thousand DKK | 5538071.968% |
| Pharma Equity Group A/S | -25.29 Million DKK | 6020.701% |
| Zealand Pharma A/S | -572.23 Million DKK | 361.696% |